Serán Bioscience Announces Investment by Vivo Capital
A majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán s service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022.
News provided by
Share this article
Share this article
BEND, Ore., Jan. 6, 2021 /PRNewswire/ Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Serán s founders who will continue to lead the Company.
Founded in 2016, Serán is a leading contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Serán s deep experience and expertise in materials science, formulation development, engineering, and phar
Provivi Team
Successfully introducing insect pheromones to control damaging pests, the increased funding will strengthen the capacity for a global roll-out SANTA MONICA, CA, UNITED STATES, December 22, 2020 /EINPresswire.com/ Provivi, Inc. ( Provivi ), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to inform the completion of a $45.5M financing round. Vivo Capital, a Palo Alto based investment fund, led the round. Returning shareholders, including Kairos Ventures, Temasek, Pontifax AgTech, Tybourne Capital, Lanx Capital, and Spruce Capital, also participated in the financing. The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico, said Dr. Pedro Coelho, Co-Founder and CEO of Provivi.